Regulatory functions of PPARβ in metabolism: implications for the treatment of metabolic syndrome

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1771, Issue 8, 2007, Pages 983-990

  Grimaldi, Paul A ^a  

^a CENTRE DE BIOCHIMIE   (France)

Author keywords

Metabolic syndrome; Pharmacology; PPAR; Skeletal muscle

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA;

ATHEROSCLEROSIS; HUMAN; LIPID METABOLISM; METABOLIC SYNDROME X; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SKELETAL MUSCLE; DRUG POTENTIATION; HEART; HEART DISEASE; HEART MUSCLE; HOMEOSTASIS; PATHOPHYSIOLOGY; PHYSIOLOGY;

HEART; HEART DISEASES; HOMEOSTASIS; HUMANS; METABOLIC SYNDROME X; MUSCLE, SKELETAL; MYOCARDIUM; PPAR-BETA;

EID: 34547673326     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2007.02.006     Document Type: Review

References (80)

1. Hill J.O., Wyatt H.R., Reed G.W., and Peters J.C. Obesity and the environment: where do we go from here?. Science 299 (2003) 853-855
2. Kiess W., Bottner A., Raile K., Kapellen T., Muller G., Galler A., Paschke R., and Wabitsch M. Type 2 diabetes mellitus in children and adolescents: a review from a European perspective. Horm. Res. 59 Suppl. 1 (2003) 77-84
3. Meigs J.B., Wilson P.W., Nathan D.M., D'Agostino R.B., Williams K., and Haffner S.M. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 52 (2003) 2160-2167
4. Wyne K.L. Metabolic syndrome: demographic features, etiology, and clinical management. Curr. Atheroscler. Rep. 7 (2005) 381-388
5. Unger R.H., and Orci L. Lipotoxic diseases of nonadipose tissues in obesity. Int. J. Obes. Relat. Metab. Disord. 24 Suppl. 4 (2000) S28-S32
6. Fasshauer M., and Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia 46 (2003) 1594-1603
7. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., and Nathan D.M. Diabetes Prevention Program Research Group, reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346 (2002) 393-403
8. Das S.K., and Chakrabarti R. Antiobesity therapy: emerging drugs and targets. Curr. Med. Chem. 13 (2006) 1429-1460
9. Krentz A.J., and Bailey C.J. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 65 (2005) 385-411
10. Ness-Abramof R., and Apovian C.M. Drug-induced weight gain. Drugs Today (Barc) 41 (2005) 547-555
11. Diamant M., and Heine R.J. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 63 (2003) 1373-1405
12. Drucker D.J. The biology of incretin hormones. Cell Metab. 3 (2006) 153-165
13. Gelfand E.V., and Cannon C.P. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opin. Investig. Drugs 15 (2006) 307-315
14. Schmidt A., Endo N., Rutledge S.J., Vogel R., Shinar D., and Rodan G.A. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol. Endocrinol. 6 (1992) 1634-1641
15. Amri E.Z., Bonino F., Ailhaud G., Abumrad N.A., and Grimaldi P.A. Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. Homology to peroxisome proliferator-activated receptors. J. Biol. Chem. 270 (1995) 2367-2371
16. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., Rosenfeld M.G., Willson T.M., Glass C.K., and Milburn M.V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395 (1998) 137-143
17. Xu H.E., Lambert M.H., Montana V.G., Parks D.J., Blanchard S.G., Brown P.J., Sternbach D.D., Lehmann J.M., Wisely G.B., Willson T.M., Kliewer S.A., and Milburn M.V. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol. Cell 3 (1999) 397-403
18. Dreyer C., Keller H., Mahfoudi A., Laudet V., Krey G., and Wahli W. Positive regulation of the peroxisomal beta-oxidation pathway by fatty acids through activation of peroxisome proliferator-activated receptors (PPAR). Biol. Cell 77 (1993) 67-76
19. Grimaldi P.A., Knobel S.M., Whitesell R.R., and Abumrad N.A. Induction of aP2 gene expression by nonmetabolized long-chain fatty acids. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 10930-10934
20. Lim H., and Dey S.K. PPAR delta functions as a prostacyclin receptor in blastocyst implantation. Trends Endocrinol. Metab. 11 (2000) 137-142
21. Shaw N., Elholm M., and Noy N. Retinoic acid is a high affinity selective ligand for the peroxisome proliferator-activated receptor beta/delta. J. Biol. Chem. 278 (2003) 41589-41592
22. Berger J., Leibowitz M.D., Doebber T.W., Elbrecht A., Zhang B., Zhou G., Biswas C., Cullinan C.A., Hayes N.S., Li Y., Tanen M., Ventre J., Wu M.S., Berger G.D., Mosley R., Marquis R., Santini C., Sahoo S.P., Tolman R.L., Smith R.G., and Moller D.E. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J. Biol. Chem. 274 (1999) 6718-6725
23. Sznaidman M.L., Haffner C.D., Maloney P.R., Fivush A., Chao E., Goreham D., Sierra M.L., LeGrumelec C., Xu H.E., Montana V.G., Lambert M.H., Willson T.M., Oliver W.R., and Sternbach D.D. Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)-synthesis and biological activity. Bioorg. Med. Chem. Lett. 13 (2003) 1517-1521
24. Michalik L., and Wahli W. Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions. Curr. Opin. Biotechnol. 10 (1999) 564-570
25. Tontonoz P., Hu E., Devine J., Beale E.G., and Spiegelman B.M. PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol. Cell. Biol. 15 (1995) 351-357
26. Muoio D.M., MacLean P.S., Lang D.B., Li S., Houmard J.A., Way J.M., Winegar D.A., Corton J.C., Dohm G.L., and Kraus W.E. Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) alpha knock-out mice. Evidence for compensatory regulation by PPAR delta. J. Biol. Chem. 277 (2002) 26089-26097
27. Surapureddi S., Yu S., Bu H., Hashimoto T., Yeldandi A.V., Kashireddy P., Cherkaoui-Malki M., Qi C., Zhu Y.J., Rao M.S., and Reddy J.K. Identification of a transcriptionally active peroxisome proliferator-activated receptor alpha-interacting cofactor complex in rat liver and characterization of PRIC285 as a coactivator. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 11836-11841
28. Lim H.J., Moon I., and Han K. Transcriptional cofactors exhibit differential preference toward peroxisome proliferator-activated receptors alpha and delta in uterine cells. Endocrinology 145 (2004) 2886-2895
29. Lee C.H., Chawla A., Urbiztondo N., Liao D., Boisvert W.A., Evans R.M., and Curtiss L.K. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 302 (2003) 453-457
30. Planavila A., Rodriguez-Calvo R., Jove M., Michalik L., Wahli W., Laguna J.C., and Vazquez-Carrera M. Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc. Res. 65 (2005) 832-841
31. Braissant O., Foufelle F., Scotto C., Dauca M., and Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha,-beta, and-gamma in the adult rat. Endocrinology 137 (1996) 354-366
32. Barak Y., Liao D., He W., Ong E.S., Nelson M.C., Olefsky J.M., Boland R., and Evans R.M. Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 303-308
33. Nadra K., Anghel S.I., Joye E., Tan N.S., Basu-Modak S., Trono D., Wahli W., and Desvergne B. Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor beta/delta. Mol. Cell. Biol. 26 (2006) 3266-3281
34. Peters J.M., Lee S.S., Li W., Ward J.M., Gavrilova O., Everett C., Reitman M.L., Hudson L.D., and Gonzalez F.J. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol. Cell. Biol. 20 (2000) 5119-5128
35. Grimaldi P.A. The roles of PPARs in adipocyte differentiation. Prog. Lipid Res. 40 (2001) 269-281
36. Di-Poi N., Michalik L., Desvergne B., and Wahli W. Functions of peroxisome proliferator-activated receptors (PPAR) in skin homeostasis. Lipids 39 (2004) 1093-1099
37. Burdick A.D., Kim D.J., Peraza M.A., Gonzalez F.J., and Peters J.M. The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation. Cell. Signal. 18 (2006) 9-20
38. Leibowitz M.D., Fievet C., Hennuyer N., Peinado-Onsurbe J., Duez H., Bergera J., Cullinan C.A., Sparrow C.P., Baffic J., Berger G.D., Santini C., Marquis R.W., Tolman R.L., Smith R.G., Moller D.E., and Auwerx J. Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett. 473 (2000) 333-336
39. Oliver W.R., Shenk J.L., Snait M.R., Russell C.S., Plunket K.D., Bodkin N.L., Lewis M.C., Winegar D.A., Sznaidman M.L., Lambert M.H., Xu H.E., Sternbach D.D., Kliewer S.A., Hansen B.C., and Willson T.M. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 5306-5311
40. Tanaka T., Yamamoto J., Iwasaki S., Asaba H., Hamura H., Ikeda Y., Watanabe M., Magoori K., Ioka R.X., Tachibana K., Watanabe Y., Uchiyama Y., Sumi K., Iguchi H., Ito S., Doi T., Hamakubo T., Naito M., Auwerx J., Yanagisawa M., Kodama T., and Sakai J. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 15924-15929
41. Wang Y.X., Lee C.H., Tiep S., Yu R.T., Ham J., Kang H., and Evans R.M. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 113 (2003) 159-170
42. Barnard R.J., Edgerton V.R., Furukawa T., and Peter J.B. Histochemical, biochemical, and contractile properties of red, white, and intermediate fibers. Am. J. Physiol. 220 (1971) 410-414
43. Pette D., Peuker H., and Staron R.S. The impact of biochemical methods for single muscle fibre analysis. Acta Physiol. Scand. 166 (1999) 261-277
44. DeFronzo R.A., Gunnarsson R., Bjorkman O., Olsson M., and Wahren J. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J. Clin. Invest. 76 (1985) 149-155
45. Goodyear L.J., and Kahn B.B. Exercise, glucose transport, and insulin sensitivity. Annu. Rev. Med. 49 (1998) 235-2361
46. Simoneau J.A., and Kelley D.E. Altered glycolytic and oxidative capacities of skeletal muscle contribute to insulin resistance in NIDDM. J. Appl. Physiol. 83 (1997) 166-171
47. Papa S. Mitochondrial oxidative phosphorylation changes in the life span. Molecular aspects and physiopathological implications. Biochim. Biophys. Acta 1276 (1996) 87-105
48. Tanner C.J., Barakat H.A., Dohm G.L., Pories W.J., MacDonald K.G., Cunningham P.R., Swanson M.S., and Houmard J.A. Muscle fiber type is associated with obesity and weight loss. Am. J. Physiol., Endocrinol. Metab. 282 (2002) E1191-E1196
49. Nyholm B., Qu Z., Kaal A., Pedersen S.B., Gravholt C.H., Andersen J.L., Saltin B., and Schmitz O. Evidence of an increased number of type IIb muscle fibers in insulin-resistant first-degree relatives of patients with NIDDM. Diabetes 46 (1997) 1822-1828
50. Zierath J.R., He L., Guma A., Odegoard Wahlstrom E., Klip A., and Wallberg-Henriksson H. Insulin action on glucose transport and plasma membrane GLUT4 content in skeletal muscle from patients with NIDDM. Diabetologia 39 (1996) 1180-1189
51. He J., Watkins S., and Kelley D.E. Skeletal muscle lipid content and oxidative enzyme activity in relation to muscle fiber type in type 2 diabetes and obesity. Diabetes 50 (2001) 817-823
52. Andersen P., and Henriksson J. Training induced changes in the subgroups of human type II skeletal muscle fibres. Acta Physiol. Scand. 99 (1977) 123-125
53. Jansson E., and Kaijser L. Muscle adaptation to extreme endurance training in man. Acta Physiol. Scand. 100 (1977) 315-324
54. Allen D.L., Harrison B.C., Maass A., Bell M.L., Byrnes W.C., and Leinwand L.A. Cardiac and skeletal muscle adaptations to voluntary wheel running in the mouse. J. Appl. Physiol. 90 (2001) 1900-1908
55. Chevillotte E., Rieusset J., Roques M., Desage M., and Vidal H. The regulation of uncoupling protein-2 gene expression by omega-6 polyunsaturated fatty acids in human skeletal muscle cells involves multiple pathways, including the nuclear receptor peroxisome proliferator-activated receptor beta. J. Biol. Chem. 276 (2001) 10853-10860
56. Holst D., Luquet S., Nogueira V., Kristiansen K., Leverve X., and Grimaldi P.A. Nutritional regulation and role of peroxisome proliferator-activated receptor delta in fatty acid catabolism in skeletal muscle. Biochim. Biophys. Acta 1633 (2003) 43-50
57. Luquet S., Lopez-Soriano J., Holst D., Fredenrich A., Melki J., Rassoulzadegan M., and Grimaldi P.A. Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB J. 17 (2003) 2299-2301
58. Wang Y.X., Zhang C.L., Yu R.T., Cho H.K., Nelson M.C., Bayuga-Ocampo C.R., Ham J., Kang H., and Evans R.M. Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol. 2 (2004) e294
59. Schuler M., Ali F., Chambon C., Duteil D., Bornert J.M., Tardivel A., Desvergne B., Wahli W., Chambon P., and Metzger D. PGC1alpha expression is controlled in skeletal muscles by PPARbeta, whose ablation results in fiber-type switching, obesity, and type 2 diabetes. Cell Metab. 4 (2006) 407-414
60. McCall G.E., Byrnes W.C., Dickinson A., Pattany P.M., and Fleck S.J. Muscle fiber hypertrophy, hyperplasia, and capillary density in college men after resistance training. J. Appl. Physiol. 81 (1996) 2004-2012
61. Watt M.J., Southgate R.J., Holmes A.G., and Febbraio M.A. Suppression of plasma free fatty acids upregulates peroxisome proliferator-activated receptor (PPAR) alpha and delta and PPAR coactivator 1alpha in human skeletal muscle, but not lipid regulatory genes. J. Mol. Endocrinol. 33 (2004) 533-544
62. Fritz T., Kramer D.K., Karlsson H.K., Galuska D., Engfeldt P., Zierath J.R., and Krook A. Low-intensity exercise increases skeletal muscle protein expression of PPARdelta and UCP3 in type 2 diabetic patients. Diabetes Metab. Res. Rev. 22 (2006) 492-498
63. Febbraio M.A., and Pedersen B.K. Contraction-induced myokine production and release: is skeletal muscle an endocrine organ?. Exerc. Sport Sci. Rev. 33 (2005) 114-119
64. Gilde A.J., van der Lee K.A., Willemsen P.H., Chinetti G., van der Leij F.R., van der Vusse G.J., Staels B., and van Bilsen M. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ. Res. 92 (2003) 518-524
65. Cheng L., Ding G., Qin Q., Xiao Y., Woods D., Chen Y.E., and Yang Q. Peroxisome proliferator-activated receptor delta activates fatty acid oxidation in cultured neonatal and adult cardiomyocytes. Biochem. Biophys. Res. Commun. 313 (2004) 277-286
66. Cheng L., Ding G., Qin Q., Huang Y., Lewis W., He N., Evans R.M., Schneider M.D., Brako F.A., Xiao Y., Chen Y.E., and Yang Q. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat. Med. 10 (2004) 1245-1250
67. Planavila A., Laguna J.C., and Vazquez-Carrera M. Nuclear factor-kappaB activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy. J. Biol. Chem. 280 (2005) 17464-17471
68. Ding G., Cheng L., Qin Q., Frontin S., and Yang Q. PPARdelta modulates lipopolysaccharide-induced TNFalpha inflammation signaling in cultured cardiomyocytes. J. Mol. Cell. Cardiol. 40 (2006) 821-828
69. Pesant M., Sueur S., Dutartre P., Tallandier M., Grimaldi P.A., Rochette L., and Connat J.L. Peroxisome proliferator-activated receptor delta (PPARdelta) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis. Cardiovasc. Res. 69 (2006) 440-449
70. van der Veen J.N., Kruit J.K., Havinga R., Baller J.F., Chimini G., Lestavel S., Staels B., Groot P.H., Groen A.K., and Kuipers F. Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1. J. Lipid Res. 46 (2005) 526-534
71. Graham T.L., Mookherjee C., Suckling K.E., Palmer C.N., and Patel L. The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice. Atherosclerosis 181 (2005) 29-37
72. Vosper H., Patel L., Graham T.L., Khoudoli G.A., Hill A., Macphee C.H., Pinto I., Smith S.A., Suckling K.E., Wolf C.R., and Palmer C.N. The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages. J. Biol. Chem. 276 (2001) 44258-44265
73. Chawla A., Lee C.H., Barak Y., He W., Rosenfeld J., Liao D., Han J., Kang H., and Evans R.M. PPARdelta is a very low-density lipoprotein sensor in macrophages. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 1268-1273
74. Lee C.H., Kang K., Mehl I.R., Nofsinger R., Alaynick W.A., Chong L.W., Rosenfeld J.M., and Evans R.M. Peroxisome proliferator-activated receptor delta promotes very low-density lipoprotein-derived fatty acid catabolism in the macrophage. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 2434-2439
75. Lee C.H., Olson P., Hevener A., Mehl I., Chong L.W., Olefsky J.M., Gonzalez F.J., Ham J., Kang H., Peters J.M., and Evans R.M. PPARdelta regulates glucose metabolism and insulin sensitivity. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 3444-3449
76. He T.C., Chan T.A., Vogelstein B., and Kinzler K.W. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99 (1999) 335-345
77. Park B.H., Vogelstein B., and Kinzler K.W. Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 2598-2603
78. Harman F.S., Nicol C.J., Marin H.E., Ward J.M., Gonzalez F.J., and Peters J.M. Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat. Med. 10 (2004) 481-483
79. Yang L., Zhou Z.G., Luo H.Z., Zhou B., Xia Q.J., and Tian C. Quantitative analysis of PPARdelta mRNA by real-time RT-PCR in 86 rectal cancer tissues. Eur. J. Surg. Oncol. 32 (2006) 181-185
80. Marin H.E., Peraza M.A., Billin A.N., Willson T.M., Ward J.M., Kennett M.J., Gonzalez F.J., and Peters J.M. Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis. Cancer Res. 66 (2006) 4394-4401